Reference | Author | Publication year | Geographic background | Gail model version | 5/10-year risk | Sample size | Mean age (years) | Study population | Risk for breast cancera | Time period | Follow-up period | E/O (95% CI) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
[9] | Bondy | 1994 | America | 1 | 5 | 1981 | 30–75 | American Cancer Society 1987 Texas Breast Screening Project (with family history of breast cancer) | High risk | 1987–1992 | 5.0 | 1.31 (0.96–1.79) |
[10] | Spiegelman | 1994 | America | 1 | 5 | 115,172 | 29–61 | Nurses’ Health Study (NHS) | General population | 1976–1981 | 6.0 | 1.33 (1.28–1.39) |
[12] | Costantino-1 | 1999 | America | 1 | 5 | 5969 | > 35 | Placebo group of Breast cancer prevention trial (BCPT) | General population | 1992–1998 | 4.03 (0.1–5.83) | 0.84 (0.73–0.97) |
[12] | Costantino-2 | 1999 | America | 2 | 5 | 5969 | > 35 | Placebo group of Breast cancer prevention trial (BCPT) | General population | 1992–1998 | 4.03 (0.1–5.83) | 1.03 (0.88–1.21) |
[11] | Rockhill | 2001 | America | 2 | 5 | 82,109 | 45–71 | Nurses’ Health Study (NHS) | General population | 1992–1997 | 5.0 | 0.94 (0.89–0.99) |
[30] | Amir | 2003 | United Kingdom | 2 | 10 | 3150 | 44 (21–73) | Women attending the Family History Screening Programme in University Hospital of South Manchester | Not defined | 1987–2001 | 5.27 (0.1–15) | 0.69 (0.54–0.90) |
[13] | Bernatsky | 2004 | America | 1 | 5 | 871 | 41 ± 13 | Systemic lupus erythematosus clinic cohorts at Canada, Northwestern and UK center | High risk | 1984–2000 | 9.1 | 0.48 (0.29–0.80) |
[14] | Olson | 2004 | America | 1 | 5 | 674 | 31–90 | Women with possible bilateral oophorectomy identified from the Mayo Clinic Surgical Index | Low risk | 1994–2004 | NA | 1.37 (0.92–2.04) |
[28] | Boyle | 2004 | Italy | 2 | 5 | 5383 | NA | Women participated in RCT of tamoxifen for breast cancer prevention in Italy | General population | 1992–2001 | 5.0 | 1.16 (0.89–1.49) |
[29] | Decarli | 2006 | Italy | 2 | 5 | 10,031 | 35–64 | Florence—European Prospective Investigation Into Cancer and Nutrition Cohort (EPIC) | General population | 1993–2002 | 9.0 | 0.93 (0.81–1.07) |
[31] | Chlebowski | 2007 | America | 2 | 5 | 147,916 | 63 (50–79) | Women’s Health Initiative (WHI) | General population | 1993–2005 | 5.0 | 0.79 (0.77–0.82) |
[15] | Tice | 2008 | America | 2 | 5 | 629,229 | 40–74 | National Cancer Institute-funded Breast Cancer Surveillance Consortium (BCSC) | General population | since 1994 | 5.3 | 0.88 (0.86–0.90) |
[16] | Schonfeld-1 | 2010 | America | 2 | 5 | 181,979 | 62.8 | National Institutes of Health-American Association of Retired Persons (NIH-AARP) | General population | 1995–2003 | 7.5 | 0.87 (0.85–0.89) |
[16] | Schonfeld-2 | 2010 | America | 2 | 5 | 64,868 | 62.3 | Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) | General population | 1993–2006 | 8.6 | 0.86 (0.82–0.90) |
[17] | Tarabishy | 2011 | America | 2 | 5 | 4726 | 18–85 | Mayo Benign Breast Disease (BBD) | High risk | 1991–1996 | 5.0 | 1.08 (0.88–1.33) |
[38] | Chay-1 | 2012 | Singapore | 3 | 5 | 28,104 | 50–64 | Singapore Breast Cancer Screening Project (SBCSP) | General population | 1997–2007 | 5.0 | 2.51 (2.14–2.96) |
[38] | Chay-2 | 2012 | Singapore | 3 | 10 | 28,104 | 50–64 | Singapore Breast Cancer Screening Project (SBCSP) | General population | 1997–2007 | 10.0 | 1.85 (1.68–2.04) |
[52] | Maclnnis | 2012 | Australia | NA | NA | 2000 | NA | Female relatives of the breast cancer cases in Australia | High risk | NA | 10.0 | 0.89 (0.73–1.09) |
[32] | Pastor-Barriuso | 2013 | Spain | 2 | 5 | 54,649 | 45–68 | Population-based Navarre Breast Cancer Screening Program (NBCSP) | General population | 1996–2005 | 7.7 | 1.46 (1.36–1.56) |
[33] | Buron | 2013 | Spain | 2 | 5 | 2200 | 49–64 | Participants with a positive screening mammogram in “Parc de Salut Mar” breast cancer screening program | High risk | 2003–2010 | 6.0 | 0.58 (0.54–0.63) |
[41] | Min-1 | 2014 | Korea | 2 | 5 | 40,229 | > 10 | Women routinely screened in Women’s Healthcare Center of Cheil General Hospital | Not defined | 1999–2004 | 5.0 | 2.46 (2.10–2.87) |
[41] | Min-2 | 2014 | Korea | 3 | 5 | 40,229 | > 10 | Women routinely screened in Women’s Healthcare Center of Cheil General Hospital | Not defined | 1999–2004 | 5.0 | 1.29 (1.11–1.51) |
[18] | Powell | 2014 | America | 2 | 5 | 12,843 | NA | Marin Women’s Study with high rate of breast cancer, null parity and delayed childbirth | High risk | 2003–2007 | 5.0 | 0.81 (0.71–0.93) |
[19] | McCarthy | 2015 | America | 2 | 5 | 464 | 48.7 ± 13.2 | Women referred for biopsy with abnormal (Breast Imaging Reporting And Data System, BI-RADS 4) mammograms at the Hospital of the University of Pennsylvania | High risk | 2003–2012 | 5.0 | 3.78 (2.78–5.13) |
[34] | Dartois | 2015 | France | 2 | 5 | 13,174 | 42–72 | Women in French E3N prospective cohort to investigate the cancer risk factors | General population | 1993–1998 | 5.0 | 0.97 (0.84–1.12) |
[39] | Hu | 2015 | China | 2 | 5 | 42,908 | 35–69 | Women participated in the breast cancer screening in Zhejiang eastern coastal areas of China | General population | 2008–2014 | 5.0 | 2.09 (1.73–2.52) |
[20] | Schonberg-1 | 2015 | America | 2 | 5 | 71,293 | 70 ± 7.0 | Nurses’ Health Study (NHS) | High risk | 2004–2009 | 5.0 | 1.20 (1.13–1.26) |
[20] | Schonberg-2 | 2015 | America | 2 | 5 | 79,611 | 71 ± 6.8 | Women’s Health Initiative (WHI), extensive study | High risk | 2005–2010 | 5.0 | 1.05 (1.00–1.10) |
[35] | Brentnall | 2015 | United Kingdom | 2 | 10 | 50,628 | 47–73 | 15 screening areas in Greater Manchester, UK | General population | 2009–2014 | 3.2 | 2.67 (2.46–2.90) |